Cost-effectiveness analysis of fruquintinib for metastatic colorectal cancer third-line treatment in China
Zhi Peng, Xingduo Hou, Yangmu Huang, Tong Xie, Xinyang Hua
BMC Cancer | BMC | Published : 2020
BACKGROUND: In this study, we analyze the cost-effectiveness of fruquintinib as third-line treatment for patients with metastatic colorectal cancer in China, especially after a recent price drop suggested by the National Healthcare Security Administration. METHODS: A Markov model was developed to investigate the cost-effectiveness of fruquintinib compared to placebo among patients with metastatic colorectal cancer. Effectiveness was measured in quality-adjusted life years (QALY). The Chinese healthcare payer's perspective was considered with a lifetime horizon, including direct medical cost (2019 US dollars [USD]). A willing-to-pay threshold was set at USD 27,130/QALY, which is three times t..View full abstract
Awarded by Clinical Medicine Plus X - Young Scholars Project of Peking University
Awarded by Beijing Municipal Administration of Hospital's Youth Program
This work was supported by Clinical Medicine Plus X - Young Scholars Project of Peking University [grant numbers PKU2019LCXQ020, PKU2018LCXQ018]; and Beijing Municipal Administration of Hospital's Youth Program [grant number 20171102]. The two funders supported the establishment of the research group and the successful publishing process.